Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Kyung Rae Ko, Sangcheol Lee, Seo Yoon Oh, Ki-duk Kim, Sin Hyung Park & Soonchul Lee. (2020) Long-Term Oral Bisphosphonate Compliance Focusing on Switching of Prescription Pattern. Patient Preference and Adherence 14, pages 2009-2016.
Read now
Read now
Mary K. Beard. (2012) Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Current Medical Research and Opinion 28:1, pages 141-147.
Read now
Read now
Luca Dalle Carbonare, Mirko Zanatta, Adriano Gasparetto & Maria Teresa Valenti. (2010) Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug, Healthcare and Patient Safety 2, pages 121-137.
Read now
Read now
Richard Derman, Joseph D Kohles & Ann Babbitt. (2009) Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. Clinical Interventions in Aging 4, pages 357-365.
Read now
Read now
Véronique Rabenda, Michaël Hiligsmann & Jean-Yves Reginster. (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy 10:14, pages 2303-2315.
Read now
Read now
Willemijn M. Meijer, Fernie J. A. Penning-van Beest, Melvin Olson & Ron M. C. Herings. (2008) Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Current Medical Research and Opinion 24:11, pages 3217-3222.
Read now
Read now
John Sunyecz. (2008) Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clinical Interventions in Aging 3:4, pages 611-627.
Read now
Read now
Colleen A. McHorney, John T. Schousboe, Richard R. Cline & Thomas W. Weiss. (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Current Medical Research and Opinion 23:12, pages 3137-3152.
Read now
Read now
Articles from other publishers (46)
Faisal I. Almohaileb & Zafar Rasheed. (2022) Comparing the Efficacies of Bisphosphonates’ Therapies for Osteoporosis Persistence and Compliance: A Systematic Review. Current Molecular Medicine 22:3, pages 274-284.
Crossref
Crossref
A.J. Singer, J. Liu, H. Yan, R.K. Stad, S.R. Gandra & A. Yehoshua. (2021) Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporosis International 32:12, pages 2473-2484.
Crossref
Crossref
Andrea Giusti, Gerolamo Bianchi, Antonella Barone & Dennis M. Black. (2021) A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clinical and Experimental Research 33:9, pages 2529-2537.
Crossref
Crossref
Y.J. Chen, P.T. Kung, W.Y. Chou & W.C. Tsai. (2020) Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan. Osteoporosis International 31:8, pages 1555-1563.
Crossref
Crossref
P.D. Miller, N. Pannacciulli, J. Malouf-Sierra, A. Singer, E. Czerwiński, H.G. Bone, C. Wang, S. Huang, A. Chines, W. Lems & J.P. Brown. (2019) Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporosis International 31:1, pages 181-191.
Crossref
Crossref
D.M. Borek, R.C. Smith, C.N. Gruber & B.L. Gruber. (2019) Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. Osteoporosis International 30:7, pages 1455-1464.
Crossref
Crossref
Stuart L. Silverman, E. Siris, D. Belazi, C. Recknor, A. Papaioannou, J. P. Brown, D. T. Gold, E. M. Lewiecki, G. Quinn, A. Balasubramanian, S. Yue, B. Stolshek & D. L. Kendler. (2018) Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Archives of Osteoporosis 13:1.
Crossref
Crossref
C. T. Yeam, S. Chia, H. C. C. Tan, Y. H. Kwan, W. Fong & J. J. B. Seng. (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis International 29:12, pages 2623-2637.
Crossref
Crossref
A. Modi, S. Sen, J. D. Adachi, S. Adami, B. Cortet, A. L. Cooper, P. Geusens, D. Mellström, J. P. Weaver, J. P. van den Bergh, P. Keown & S. Sajjan. (2017) The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study. Osteoporosis International 29:2, pages 329-337.
Crossref
Crossref
P. Hadji, I. Kyvernitakis, P. H. Kann, C. Niedhart, L. C. Hofbauer, H. Schwarz, A. A. Kurth, F. Thomasius, M. Schulte, M. Intorcia, E. Psachoulia & T. Schmid. (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporosis International 27:10, pages 2967-2978.
Crossref
Crossref
Jae-Hwi NhoYoung-Kyun LeeYong-Chan HaChung-Hyun KimYou-Sung SuhKyung-Hoi Koo. (2016) Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?. Journal of Bone Metabolism 23:2, pages 51.
Crossref
Crossref
L. Karlsson, J. Lundkvist, E. Psachoulia, M. Intorcia & O. Ström. (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporosis International 26:10, pages 2401-2411.
Crossref
Crossref
Ankita Modi, Deborah T. Gold, Xiaoqin Yang, Chun-Po Steve Fan & Shiva G. Sajjan. (2015) Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population. Journal of Managed Care & Specialty Pharmacy 21:9, pages 811-821.
Crossref
Crossref
M. M. Bonafede, N. Shi, A. G. Bower, R. L. Barron, A. Grauer & D. B. Chandler. (2015) Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporosis International 26:3, pages 1203-1212.
Crossref
Crossref
Andrea M. Burden, J. Michael Paterson, Andrea Gruneir & Suzanne M. Cadarette. (2015) Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiology and Drug Safety 24:1, pages 67-74.
Crossref
Crossref
S. W. Wade, S. Satram-Hoang & B. S. Stolshek. (2014) Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™. Osteoporosis International 25:9, pages 2279-2290.
Crossref
Crossref
P. Hadji, D. Felsenberg, M. Amling, L. C. Hofbauer, J. A. Kandenwein & A. Kurth. (2013) The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporosis International 25:1, pages 339-347.
Crossref
Crossref
Y.-K. Lee, Y.-C. Ha, H. J. Choi, S. Jang, C. Park, Y.-T. Lim & C. S. Shin. (2013) Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporosis International 24:11, pages 2887-2892.
Crossref
Crossref
Y.-K. Lee, Y.-C. Ha, B.-H. Yoon & K.-H. Koo. (2012) Incidence of second hip fracture and compliant use of bisphosphonate. Osteoporosis International 24:7, pages 2099-2104.
Crossref
Crossref
Y.-K. Soong, K.-S. Tsai, H.-Y. Huang, R.-S. Yang, J.-F. Chen, P. C.-H. Wu & K.-E. Huang. (2012) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporosis International 24:2, pages 511-521.
Crossref
Crossref
Sang-Hwan KimYoung-Bong KoYoung-Kyun LeeSeok-Woo HongHyung-Jin ChoiYong-Chan HaChan-Soo Shin. (2013) National Utilization of Calcium Supplements in Patients with Osteoporotic Hip Fracture in Korea. Journal of Bone Metabolism 20:2, pages 99.
Crossref
Crossref
Deborah T. Gold. 2013. Osteoporosis. Osteoporosis
1909
1921
.
Cyrille B Confavreux, Florence Canoui-Poitrine, Anne-Marie Schott, Véronique Ambrosi, Valérie Tainturier & Roland D Chapurlat. (2012) Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. European Journal of Endocrinology 166:4, pages 735-741.
Crossref
Crossref
John S Sampalis, Jonathan D Adachi, Emmanouil Rampakakis, Julie Vaillancourt, Angela Karellis & Christian Kindundu. (2011) Long‐term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. Journal of Bone and Mineral Research 27:1, pages 202-210.
Crossref
Crossref
François-Emery Cotté & Gérard De Pouvourville. (2011) Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Services Research 11:1.
Crossref
Crossref
Susan Ross, Ebony Samuels, Kerry Gairy, Sheikh Iqbal, Enkhe Badamgarav & Ethel Siris. (2011) A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence. Value in Health 14:4, pages 571-581.
Crossref
Crossref
Milica Nikitovic, Daniel H. Solomon & Suzanne M. Cadarette. (2010) Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Therapeutic Advances in Chronic Disease 1:4, pages 149-162.
Crossref
Crossref
Stuart L. Silverman. (2010) Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies. Calcified Tissue International 87:5, pages 375-384.
Crossref
Crossref
Robert A. Yood, Susan E. Andrade, Kathleen M. Mazor, Hassan Fouayzi, Wing Chan & Kristijan Kahler. (2010) Bone density consequences of initiation and compliance with therapy for osteoporosis. Arthritis Care & Research 62:10, pages 1440-1445.
Crossref
Crossref
D. L. Kendler, L. Bessette, C. D. Hill, D. T. Gold, R. Horne, S. F. Varon, J. Borenstein, H. Wang, H.-S. Man, R. B. Wagman, S. Siddhanti, D. Macarios & H. G. Bone. (2009) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporosis International 21:5, pages 837-846.
Crossref
Crossref
M. M. Wilkes, R. J. Navickis, W. W. Chan & E. M. Lewiecki. (2009) Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporosis International 21:4, pages 679-688.
Crossref
Crossref
F.-E. Cotté, P. Fardellone, F. Mercier, A.-F. Gaudin & C. Roux. (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporosis International 21:1, pages 145-155.
Crossref
Crossref
Valentina I. Petkov & Melissa I. Williams. 2010. Osteoporosis. Osteoporosis
605
620
.
S. Boonen, R. Kay, C. Cooper, P. Haentjens, D. Vanderschueren, F. Callewaert, K. Milisen & S. Ferrari. (2009) Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. International Journal of Clinical Practice 63:12, pages 1792-1804.
Crossref
Crossref
E. Michael Lewiecki. (2009) Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis. Journal of Women's Health 18:10, pages 1615-1626.
Crossref
Crossref
Sydney Lou BonnickStuart SilvermanS. Bobo TannerMark MartensGloria BachmannJoseph D. KohlesRoberto Civitelli. (2009) Patient Satisfaction in Postmenopausal Women Treated with a Weekly Bisphosphonate Transitioned to Once-Monthly Ibandronate. Journal of Women's Health 18:7, pages 935-943.
Crossref
Crossref
Ethel S. Siris, Peter L. Selby, Kenneth G. Saag, Fredrik Borgström, Ron M.C. Herings & Stuart L. Silverman. (2009) Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe. The American Journal of Medicine 122:2, pages S3-S13.
Crossref
Crossref
C. Roerholt, P. Eiken & B. Abrahamsen. (2008) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporosis International 20:2, pages 299-307.
Crossref
Crossref
François-Emery Cotté, Florence Mercier & Gérard De Pouvourville. (2008) Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case—control analysis. Clinical Therapeutics 30:12, pages 2410-2422.
Crossref
Crossref
Deborah T. Gold. 2008. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
254
256
.
J. A. Sunyecz, L. Mucha, O. Baser, C. E. Barr & M. M. Amonkar. (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporosis International 19:10, pages 1421-1429.
Crossref
Crossref
E. Michael Lewiecki, Ann M. Babbitt, Veronica K. Piziak, Zafer E. Ozturk & Henry G. Bone. (2008) Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12-Month, Open-Label, Prospective Evaluation. Clinical Therapeutics 30:4, pages 605-621.
Crossref
Crossref
Stuart L. Silverman & Deborah T. Gold. (2008) Compliance and persistence with osteoporosis therapies. Current Rheumatology Reports 10:2, pages 118-122.
Crossref
Crossref
F. J. A. Penning-van Beest, J. A. Erkens, M. Olson & R. M. C. Herings. (2007) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporosis International 19:4, pages 511-517.
Crossref
Crossref
Stuart L. Silverman, Deborah T. Gold & Joyce A. Cramer. (2007) Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies. Southern Medical Journal 100:12, pages 1214-1218.
Crossref
Crossref
Deborah T Gold & Stuart L Silverman. (2007) Compliance and persistence with osteoporosis therapies: we can do better. Future Rheumatology 2:5, pages 443-445.
Crossref
Crossref